Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.
Vandita Jadeja NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble…
Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change…
Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch…
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded,…
Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears…
Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds…
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why…
Vandita Jadeja Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at…
Omor Ibne Ehsan Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia's most valuable competitive advantage disappears entirely.
